Stem cells in retinal regeneration: past, present and future

Ramsden, Conor; Powner, Michael B.; Carr, Amanda-Jayne F.; Smart, Matthew; Cruz, Lyndon da; Coffey, Peter

doi:10.1242/dev.092270

Cited by 230 publications

(224 citation statements)

References 87 publications

Supporting

Mentioning

202

Contrasting

Unclassified

Order By: Relevance

“…[7] With the rapid exploration of iPSC technology and the burgeoning research output, it is not surprising that the first trial of iPSC for the treatment of agerelated macular degeneration is underway. [8] However, the rise of iPSC technology has brought into focus many new ethical questions that must be addressed and resolved.…”

mentioning

confidence: 99%

Towards guidelines for informed consent for prospective stem cell research

Greenberg¹,

Smith²,

Burman³

et al. 2015

S Afr J BL

View full text Add to dashboard Cite

mentioning

confidence: 99%

Towards guidelines for informed consent for prospective stem cell research

Greenberg¹,

Smith²,

Burman³

et al. 2015

S Afr J BL

View full text Add to dashboard Cite

“…However, this branch of surgery opened an important new frontier, and operations in the subretinal space are key to the success of two new areas of therapy, namely gene therapy 62 and RPE transplantation. 63 It is very likely that these two areas will be major subjects when the history of the next 25 years of vitreoretinal surgery is written. Figure 3 Autofluorescence image of a subfoveal RPE patch.…”

Section: Submacular Surgerymentioning

confidence: 99%

25th RCOphth Congress, President's Session paper: 25 years of progress in vitreoretinal surgery

Aylward

2014

Eye

View full text Add to dashboard Cite

Over the past 25 years, vitreoretinal surgery has undergone considerable change in technology, techniques, and professional organisation. Many conditions that were considered untreatable in 1988 are now treated routinely by vitreoretinal surgeons. Over the same period, vitreoretinal surgery has become a separate subspecialty with its own scientific meetings and professional organisation. This article describes a noncomprehensive selection of some of the highlights of the past 25 years, including the establishment and growth of BEAVRS (British and Eire Association of Vitreoretinal Surgeons), the revolution in the management of macular holes, the development of submacular surgery, and the introduction of sutureless vitrectomy.

show abstract

“…Once fully differentiated, we employ multiple techniques to characterize the cells anatomically and functionally to ensure that they will serve as adequate replacements for diseased RPE. The description of these techniques, and protocol for implanting the iPS-RPE in the subretinal space of rodents, are beyond the scope of this methods paper and have been previously published 12,32,41 .…”

Section: Introductionmentioning

confidence: 99%

Efficient Derivation of Retinal Pigment Epithelium Cells from Stem Cells

Westenskow

Sedillo

Barnett

et al. 2015

JoVE

View full text Add to dashboard Cite

No cure has been discovered for age-related macular degeneration (AMD), the leading cause of vision loss in people over the age of 55. AMD is complex multifactorial disease with an unknown etiology, although it is largely thought to occur due to death or dysfunction of the retinal pigment epithelium (RPE), a monolayer of cells that underlies the retina and provides critical support for photoreceptors. RPE cell replacement strategies may hold great promise for providing therapeutic relief for a large subset of AMD patients, and RPE cells that strongly resemble primary human cells (hRPE) have been generated in multiple independent labs, including our own. In addition, the uses for iPS-RPE are not limited to cell-based therapies, but also have been used to model RPE diseases. These types of studies may not only elucidate the molecular bases of the diseases, but also serve as invaluable tools for developing and testing novel drugs. We present here an optimized protocol for directed differentiation of RPE from stem cells. Adding nicotinamide and either Activin A or IDE-1, a small molecule that mimics its effects, at specific time points, greatly enhances the yield of RPE cells. Using this technique we can derive large numbers of low passage RPE in as early as three months. Video LinkThe video component of this article can be found at

show abstract

Stem cells in retinal regeneration: past, present and future

Cited by 230 publications

References 87 publications

Towards guidelines for informed consent for prospective stem cell research

Towards guidelines for informed consent for prospective stem cell research

25th RCOphth Congress, President's Session paper: 25 years of progress in vitreoretinal surgery

Efficient Derivation of Retinal Pigment Epithelium Cells from Stem Cells

Contact Info

Product

Resources

About